Protective immunity against neu-positive carcinomas elicited by electroporation of plasmids encoding decreasing fragments of rat neu extracellular domain

Human Gene Therapy

Volumn 19, Issue 3, 2008, Pages 229-239

  Rolla, Simona ^a   Marchini, Cristina ^b   Malinarich, Silvia ^a   Quaglino, Elena ^a   Lanzardo, Stefania ^a   Montani, Maura ^b   Iezzi, Manuela ^c   Angeletti, Mauro ^b   Ramadori, Giorgio ^b   Forni, Guido ^a   Cavallo, Federica ^a,d   Amici, Augusto ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; PROTEIN P185;

AMINO ACID COMPOSITION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CARCINOGENESIS; CARCINOMA; CELL MEMBRANE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ELECTROPORATION; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; ONCOGENE NEU; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; TRANSGENIC ANIMAL; WILD TYPE;

ANIMALS; ANTIBODIES; CELL LINE; ELECTROPORATION; FEMALE; FIBROBLASTS; GENE THERAPY; GENES, ERBB-2; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PLASMIDS; RATS; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC;

MUS; RATTUS;

EID: 41149167241     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.196     Document Type: Article

References (27)

1. AMBROSINO, E., SPADARO, M., IEZZI, M., CURCIO, C., FORNI, G., MUSIANI, P., WEI, W.Z., and CAVALLO, F. (2006). Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res. 66, 7734-7740.
2. BOGGIO, K., NICOLETTI, G., DI CARLO, E., CAVALLO, F., LANDUZZI, L., MELANI, C., GIOVARELLI, M., ROSSI, I., NANNI, P., DE GIOVANNI, C., BOUCHARD, P., WOLF, S., MODESTI, A., MUSIANI, P., LOLLINI, P.L., COLOMBO, M.P., and FORNI, G. (1998). Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J. Exp. Med. 188, 589-596.
3. CAPPELLO, P., TRIEBEL, F., IEZZI, M., CAORSI, C., QUAGLINO, E., LOLLINI, P.L., AMICI, A., DI CARLO, E., MUSIANI, P., GIOVARELLI, M., and FORNI, G. (2003). LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res. 63, 2518-2525.
4. + T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene transfection. J. Immunol. 149, 3627-3635.
5. CAVALLO, F., OFFRINGA, R., VAN DER BURG, S.H., FORNI, G., and MELIEF, C.J. (2006). Vaccination for treatment and prevention of cancer in animal models. Adv. Immunol. 90, 175-213.
6. CHO, H.S., MASON, K., RAMYAR, K.X., STANLEY, A.M., GABELLI, S.B., DENNEY, D.W., Jr., and LEAHY, D.J. (2003). Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421, 756-760.
7. CURCIO, C., DI CARLO, E., CLYNES, R., SMYTH, M.J., BOGGIO, K., QUAGLINO, E., SPADARO, M., COLOMBO, M.P., AMICI, A., LOLLINI, P.L., MUSIANI, P., and FORNI, G. (2003). Nonredundant roles of antibody, cytokines and perforin for the immune eradication of established Her-2/neu carcinomas. J. Clin. Invest. 111, 1161-1170.
8. DISIS, M.L., CALENOFF, E., MCLAUGHLIN, G., MURPHY, A.E., CHEN, W., GRONER, B., JESCHKE, M., LYDON, N., MCGLYNN, E., LIVINGSTON, R.B., MOE, R., and CHEEVER, M.A. (1994). Existent T cell and antibody immunity to Her-2/neu protein in patients with breast cancer. Cancer Res. 54, 16-20.
9. DRANOFF, G. (2003). Coordinated tumor immunity. J. Clin. Invest. 111, 1116-1118.
10. ENGELHORN, M.E., GUEVARA-PATIÑO, J.A., NOFFZ, G., HOOPER, A.T., LOU, O., GOLD, J.S., KAPPEL, B.J., and HOUGHTON, A.N. (2006). Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat. Med. 12,198-206.
11. LOLLINI, P.L., CAVALLO, F., NANNI, P., and FORNI, G. (2006). Vaccines for cancer prevention. Nat. Rev. Cancer 6, 204-216.
12. MATTHIESSEN, L., LUCARONI, B., and SACHEZ, E. (2003). Towards responsible animal research. Addressing the ethical dimension of animal experimentation and implementing the 'Three R's' principle in biomedical research. EMBO Rep. 4, 104-107.
13. MELANI, C., CHIODONI, C., FORNI, G., and COLOMBO, M.P. (2003). Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102, 2138-2145.
14. NAGATA, Y., FURUGEN, R., HIASA, A., IKEDA, H., OHTA, N., FURUKAWA, K., NAKAMURA, H., FURUKAWA, K., KANEMATSU, T., and SHIKU, H. (1997). Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J. Immunol. 159, 1336-1343.
15. NANNI, P., LANDUZZI, L., NICOLETTI, G., DE GIOVANNI, C., ROSSI, I., CROCI, S., ASTOLFI, A., IEZZI, M., DI CARLO, E., MUSIANI, P., FORNI, G., and LOLLINI, P.L. (2004). Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is γ-interferon and B cell dependent. J. Immunol. 173, 2288-2296.
16. PANNELLINI, T., FORNI, G., and MUSIANI, P. (2004). Immunobiology of Her-2/neu transgenic mice. Breast Dis. 20, 33-42.
17. PEOPLES, G.E., GURNEY, J.M., HUEMAN, M.T., WOLL, M.M., RYAN, G.B., STORRER, C.E., FISHER, C., SHRIVER, C.D., IOANNIDES, C.G., and PONNIAH, S. (2005). Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J. Clin. Oncol. 23, 7536-7545.
18. + lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J. Immunol. 153, 5659-5673.
19. PIECHOCKI, M.P., PILON, S.A., and WEI, W.Z. (2001). Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. J. Immunol. 167, 3367-3374.
20. PROSS, H.F., BAINES, M.G., RUBIN, P., SHRAGGE, P., and PATTERSON, M.S. (1981). Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J. Clin. Immunol. 1, 51-63.
21. QUAGLINO, E., IEZZI, M., MASTINI, C., AMICI, A., PERICLE, F., DI CARLO, E., PUPA, S.M., DE GIOVANNI, C., SPADARO, M., CURCIO, C., LOLLINI, P.L., MUSIANI, P., FORNI, G., and CAVALLO, F. (2004a). Electroporated DNA vaccine clears away multifocal mammary carcinomas in Her-2/neu transgenic mice. Cancer Res. 64, 2858-2864.
22. QUAGLINO, E., ROLLA, S., IEZZI, M., SPADARO, M., MUSIANI, P., DE GIOVANNI, C., LOLLINI, P.L., LANZARDO, S., FORNI, G., SANGES, R., CRISPI, S., DE LUCA, P., CALOGERO, R., and CAVALLO, F. (2004b). Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J. Clin. Invest. 113, 709-717.
23. ROLLA, S., NICOLÓ, C., MALINARICH, S., ORSINI, M., FORNI, G., CAVALLO, F., and RIA, F. (2006). Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J. Immunol. 177, 7626-7633.
24. ROVERO, S., AMICI, A., CARLO, E.D., BEI, R., NANNI, P., QUAGLINO, E., PORCEDDA, P., BOGGIO, K., SMORLESI, A., LOLLINI, P.L., LANDUZZI, L., COLOMBO, M.P., GIOVARELLI, M., MUSIANI, P., and FORNI, G. (2000). DNA vaccination against rat Her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol. 165, 5133-5142.
25. SLAMON, D.J., CLARK, G.M., WONG, S.G., LEVIN, W.J., ULLRICH, A., and MCGUIRE, W.L. (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
26. SPADARO, M., AMBROSINO, E., IEZZI, M., DI CARLO, E., SACCHETTI, P., CURCIO, C., AMICI, A., WEI, W.Z., MUSIANI, P., LOLLINI, P.L., CAVALLO, F., and FORNI, G. (2005). Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin. Cancer Res. 11, 1941-1952.
27. YARDEN, Y., and SLIWKOWSKI, M.X. (2001). Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2, 127-137.